

Join Us
For A Free
Virtual Forum



VIRTUAL FORUM



Neuromodulation Techniques: State Of The Science

Wednesday, July 11, 2018 | 12pm ET | 9am PT

Clinicians managing patients with behavioral health issues are presented with various diagnostic and treatment challenges, spanning the areas of neurobiology, adherence, safety, and medication tolerability. Currently available pharmacotherapeutic, psychotherapeutic, and combination therapies often provide inadequate or only partial responses, leaving patients with a host of residual symptoms. Neuromodulation techniques, including transcranial magnetic stimulation (TMS), deep brain stimulation (DBS) and others, have been gaining favor among experts as alternative options for addressing those experiencing inadequate response with more traditional treatment regimens.

In this Virtual Forum, join Philip G. Janicak, MD, and Michael Thase, MD, as they discuss the state of the science in neuromodulation techniques. Speakers will discuss their perspectives and the supporting evidence for various forms of neuromodulation in the treatment of mental health disorders, with a focus on depression. Speakers are paid consultants for Otsuka Pharmaceutical Development & Commercialization, Inc.

Philip G. Janicak, MD

Adjunct Professor, Department of Psychiatry & Behavioral Sciences,
Northwestern University, Feinberg School of Medicine;
& Director, Transcranial Magnetic Stimulation Center,
Edward/Elmhurst Healthcare



Michael Thase, MD

Professor, Psychiatry, & Director, Mood & Anxiety
Disorders Treatment & Research Program,
University of Pennsylvania Perelman
School of Medicine



Mark Tacelosky, PharmD, Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc., will be the moderator of this event



Visit www.PsychU.org/events/virtual-forums
to learn more and register today.



Tune In To PsychU Radio: www.PsychU.org/radio



Follow Us On Twitter: [@PsychUCommunity](https://twitter.com/PsychUCommunity)

PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU's contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
Copyright © 2018 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD

December 2017 MRC2.CORPX.02248